S0412, Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

This study is ongoing, but not recruiting participants.

Study NCT00101114 Information provided by Southwest Oncology Group

First Received: January 7, 2005 Last Updated: July 21, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Goldman BH, Lara PN, Beer TM, et al.: Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): an analysis of SWOG 0412. [Abstract] J Clin Oncol 25 (Suppl 18): A-5108, 261s, 2007.

Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED; Southwest Oncology Group. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 1;25(22):3296-301.